<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">




NORDIC CEO FORUM

DOWNLOAD THE 2018 BROCHURE
ENQUIRE HERE

 2018 NORDIC CEO FORUM ( Held on Wednesday 29th August)   

Co-Hosted by:

Nasdaq17_313+BK.png         Vinge.png          PWC 

LSX’s 2018 Nordic CEO Forum provided a unique, powerful and valuable space for the candid sharing of experience between the sector’s most senior executives.

The Biotech and Money/LSX CEO Forum for UK's biotech leaders has been running biannually for 4 years, with 7 iterations to date, and is a highly popular format and unique opportunity to connect executives leaders.

The Nordic CEO forum is an invitation only roundtable forum where all participants are active discussants and have an equal voice, and is exclusively for listed company CXOs, to ensure conversation is meaningful and tailored. The forum follows a strict Chatham House Rule policy and includes case study peer review and a general discussion focused on brainstorming solutions to the collective challenges of the company CxOs in the sector.

What you can expect:

STATE OF THE MARKET PRESENTATIONS
PERSPECTIVES AND LATEST TRENDS IN CAPITAL MARKETS, M&A AND DEALS

Nasdaq
Peter Legind-Hansen, Managing Director, Nasdaq
Håkan Sjögren, Managing Director, Nasdaq

PwC
Magnus Lagerberg, Partner, PwC
Johan Engstam, Partner, PwC

LEGAL TRENDS IN 2018 & NEAR TERM OUTLOOK

Vinge
Erik Sjöman, Partner, Vinge
Dain Hård Nevonen, Partner, Vinge

INTERACTIVE, PEER LED CASE STUDIES
RECENT TRANSACTIONS, DEALS, FUNDRAISINGS; DEEP DIVES ON BUSINESS MODEL INNOVATIONS; COMPANY TURNAROUNDS AND OTHER WAR STORIES

Secondary Fundraising: Directed share issue to develop pipeline
Goran Forsberg, CEO, Cantargia

Uplisting: Immunovia Stockholm First North to Main Market
Mats Grahn, CEO, Immunovia

Dual-listing: Zealand Pharma, Copenhagen to Nasdaq
Mats Blom, CFO, Zealand Pharma

Vinge
Jesper Ottergren, Partner + Client CEO

Major Deal: Alexion acquisition of Wilson Therapeutics
Jonas Hansson, CEO, Wilson Therapeutics

GENERAL DISCUSSION

MiFID II – what affect is this having on listed companies? How can companies get the coverage they need? How much coverage and how much to spend?
The power of social media and B2B marketing and promotion to make the most of your story
Solutions and strategies for mitigating low liquidity in Nordic public markets
Building out the board with the right skill sets, particularly fundraising expertise and experience
What are the major considerations for considering dual-listing?
Balancing shareholders’ needs, patient access, perception of the company, and perception in the industry

ACTIONABLE OUTCOMES

THE FORUM IS A CATALYST FOR PROJECTS, RESEARCH AND/OR OTHER IMPACTFUL OUTCOMES FOR THE SECTOR